Stock listing
Shenzhen:300119 Tianjin Ringpu Bio-technology Co., Ltd. (瑞普生物) 股价
Follow Tianjin Ringpu Bio-technology Co., Ltd. into a list and get an email when it puts out news.
Share price · SZSE:300119
¥15.23 CNY -0.81 (-5.0%)
Close on Nov 20, 2026
- Day range
- ¥15.13 – ¥15.67 CNYNov 20, 2026
- Volume
- 4.03M sharesNov 20, 2026
- Market cap
- ¥7.08B CNYAt the close on Nov 20, 2026 · price × 464.8M shares outstanding
- 52-week range
- ¥13.91 – ¥21.51 CNYLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- ¥71.79M CNYMedian day 3.78M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · SZSE:300119 · CNY, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| ¥15.23 | -0.81 | -5.0% | ¥15.67 | ¥15.67 | ¥15.13 | 4,027,600 | |
| ¥16.04 | -0.50 | -3.0% | ¥16.62 | ¥16.70 | ¥15.97 | 4,053,700 | |
| ¥16.54 | -0.07 | -0.4% | ¥16.51 | ¥16.82 | ¥16.49 | 2,761,500 | |
| ¥16.61 | +0.20 | +1.2% | ¥16.37 | ¥16.68 | ¥16.28 | 2,535,347 | |
| ¥16.41 | -0.07 | -0.4% | ¥16.50 | ¥16.79 | ¥16.38 | 3,208,900 | |
| ¥16.48 | -0.12 | -0.7% | ¥16.66 | ¥16.77 | ¥16.44 | 2,528,500 | |
| ¥16.60 | -0.22 | -1.3% | ¥16.86 | ¥16.88 | ¥16.60 | 2,822,500 | |
| ¥16.82 | -0.24 | -1.4% | ¥17.16 | ¥17.16 | ¥16.82 | 2,436,667 | |
| ¥17.06 | -0.21 | -1.2% | ¥17.34 | ¥17.37 | ¥16.88 | 3,742,500 | |
| ¥17.27 | +0.05 | +0.3% | ¥16.90 | ¥17.55 | ¥16.81 | 4,553,232 | |
| ¥17.22 | +0.32 | +1.9% | ¥16.92 | ¥17.22 | ¥16.80 | 3,857,500 | |
| ¥16.90 | -0.01 | -0.1% | ¥16.88 | ¥17.10 | ¥16.71 | 4,470,600 | |
| ¥16.91 | +0.11 | +0.7% | ¥16.84 | ¥17.05 | ¥16.71 | 4,292,500 | |
| ¥16.80 | +0.53 | +3.3% | ¥16.20 | ¥16.96 | ¥16.10 | 5,886,500 | |
| ¥16.27 | +0.06 | +0.4% | ¥16.16 | ¥16.65 | ¥16.07 | 3,634,192 | |
| ¥16.21 | -0.25 | -1.5% | ¥16.49 | ¥16.63 | ¥16.15 | 4,065,800 | |
| ¥16.46 | +1.22 | +8.0% | ¥15.64 | ¥16.59 | ¥15.64 | 7,647,900 | |
| ¥15.24 | -1.02 | -6.3% | ¥16.21 | ¥16.43 | ¥15.21 | 5,737,000 | |
| ¥16.26 | +0.09 | +0.6% | ¥16.34 | ¥16.48 | ¥16.12 | 2,257,792 | |
| ¥16.17 | +0.15 | +0.9% | ¥15.94 | ¥16.24 | ¥15.70 | 3,285,400 | |
| ¥16.02 | -0.42 | -2.6% | ¥16.43 | ¥16.55 | ¥16.02 | 2,017,400 | |
| ¥16.44 | +0.05 | +0.3% | ¥16.39 | ¥16.69 | ¥16.36 | 2,575,100 | |
| ¥16.39 | +0.11 | +0.7% | ¥16.30 | ¥16.68 | ¥16.24 | 2,878,600 | |
| ¥16.28 | +0.23 | +1.4% | ¥16.03 | ¥16.37 | ¥16.00 | 2,335,800 | |
| ¥16.05 | -0.05 | -0.3% | ¥16.18 | ¥16.52 | ¥15.91 | 3,817,219 | |
| ¥16.10 | -0.38 | -2.3% | ¥16.33 | ¥16.46 | ¥15.96 | 3,647,800 | |
| ¥16.48 | +0.23 | +1.4% | ¥16.21 | ¥16.63 | ¥16.17 | 3,107,900 | |
| ¥16.25 | -0.22 | -1.3% | ¥16.49 | ¥16.49 | ¥15.98 | 3,134,900 | |
| ¥16.47 | -0.34 | -2.0% | ¥16.82 | ¥16.97 | ¥16.38 | 2,668,200 | |
| ¥16.81 | +0.19 | +1.1% | ¥16.55 | ¥16.89 | ¥16.38 | 3,215,124 | |
| ¥16.62 | -0.14 | -0.8% | ¥16.99 | ¥17.28 | ¥16.50 | 3,516,100 | |
| ¥16.76 | +0.26 | +1.6% | ¥16.53 | ¥16.90 | ¥16.50 | 2,587,824 | |
| ¥16.50 | -0.05 | -0.3% | ¥16.51 | ¥16.78 | ¥16.38 | 2,288,700 | |
| ¥16.55 | -0.11 | -0.7% | ¥16.66 | ¥16.81 | ¥16.38 | 3,443,500 | |
| ¥16.66 | -0.48 | -2.8% | ¥17.16 | ¥17.33 | ¥16.62 | 3,637,977 | |
| ¥17.14 | -0.08 | -0.5% | ¥17.19 | ¥17.29 | ¥17.05 | 3,061,000 | |
| ¥17.22 | +0.06 | +0.3% | ¥17.15 | ¥17.34 | ¥16.97 | 3,363,200 | |
| ¥17.16 | +0.40 | +2.4% | ¥16.77 | ¥17.30 | ¥16.75 | 4,816,906 | |
| ¥16.76 | -0.52 | -3.0% | ¥17.29 | ¥17.42 | ¥16.68 | 6,295,472 | |
| ¥17.28 | +0.07 | +0.4% | ¥17.21 | ¥17.38 | ¥17.13 | 3,095,500 | |
| ¥17.21 | -0.02 | -0.1% | ¥17.18 | ¥17.71 | ¥17.10 | 4,675,924 | |
| ¥17.23 | -0.10 | -0.6% | ¥17.29 | ¥17.69 | ¥17.12 | 2,827,300 | |
| ¥17.33 | +0.10 | +0.6% | ¥17.23 | ¥17.38 | ¥16.91 | 3,648,176 | |
| ¥17.23 | -0.59 | -3.3% | ¥17.71 | ¥17.77 | ¥17.08 | 3,950,400 | |
| ¥17.82 | -0.14 | -0.8% | ¥17.83 | ¥18.02 | ¥17.57 | 3,479,976 | |
| ¥17.96 | -0.16 | -0.9% | ¥18.02 | ¥18.18 | ¥17.81 | 3,982,576 | |
| ¥18.12 | -0.06 | -0.3% | ¥18.25 | ¥18.33 | ¥17.90 | 5,210,100 | |
| ¥18.18 | +0.49 | +2.8% | ¥17.64 | ¥18.31 | ¥17.55 | 8,482,000 | |
| ¥17.69 | +0.43 | +2.5% | ¥17.27 | ¥17.98 | ¥17.18 | 5,348,900 | |
| ¥17.26 | -0.58 | -3.3% | ¥17.81 | ¥18.05 | ¥17.25 | 4,850,800 | |
| ¥17.84 | +0.31 | +1.8% | ¥17.58 | ¥18.02 | ¥17.43 | 6,666,976 | |
| ¥17.53 | +0.23 | +1.3% | ¥17.25 | ¥17.86 | ¥17.25 | 5,671,777 | |
| ¥17.30 | 0.00 | 0.0% | ¥17.36 | ¥17.56 | ¥17.13 | 5,255,897 | |
| ¥17.30 | +0.10 | +0.6% | ¥17.18 | ¥17.37 | ¥17.00 | 4,256,797 | |
| ¥17.20 | +0.35 | +2.1% | ¥16.83 | ¥17.22 | ¥16.59 | 5,548,290 | |
| ¥16.85 | -0.63 | -3.6% | ¥17.29 | ¥17.60 | ¥16.82 | 7,605,800 | |
| ¥17.48 | +0.14 | +0.8% | ¥17.17 | ¥17.62 | ¥17.17 | 4,272,386 | |
| ¥17.34 | -0.58 | -3.2% | ¥17.86 | ¥18.13 | ¥17.14 | 6,660,776 | |
| ¥17.92 | -0.69 | -3.7% | ¥18.35 | ¥18.42 | ¥17.72 | 8,362,207 | |
| ¥18.61 | +0.20 | +1.1% | ¥18.77 | ¥19.59 | ¥18.58 | 9,151,378 |
Splits
3 splits since 2011 · SZSE:300119 · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1.9936-for-1 | Split | |
| 13-for-10 | Split | |
| 2-for-1 | Split |
- Ticker
- Shenzhen:300119
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- Shenzhen
- Currency
- CNY
Tianjin Ringpu Bio-technology Co., Ltd. on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
Valuation
P/E 21.0× against a median of 22.4×: 4th lowest of 8 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- ¥5.82B CNY
- P/E
- 21.0×
- EV/sales
- 1.6×
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 1.5×
- Gross margin
- 39.6%
- Operating margin
- 13.0%
- Net margin
- 9.6%
- Debt to equity
- 0.1×
- Beta
- No index for this market yet
Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Tianjin Ringpu Bio-technology Co., Ltd. Class A · SZSE:300119 | US$1.06B | US$873.7M | 21.0× | 1.6× | n/a | 1.5× | 9.6% | 0.1× | n/a |
| Idorsia Ltd. · SIX:IDIA | US$1.15B | US$2.66B | n/a | 10.2× | n/a | n/a | −128.8% | n/a | n/a |
| Harrow, Inc. · NASDAQ:HROW | US$1.14B | US$1.36B | n/a | 4.5× | 188× | 39.1× | −9.4% | 10.0× | 1.31 |
| Changzhou Qianhong Bio-Pharma Co., Ltd. Class A · SZSE:002550 | US$1.12B | US$929.9M | 32.3× | 4.1× | n/a | 2.7× | 15.3% | 0.0× | n/a |
| GC Biopharma Corp. · KRX:006280 | US$1.10B | US$1.30B | n/a | 0.9× | 13.2× | 1.2× | −2.5% | 0.3× | n/a |
| Vetoquinol SA · EURONEXT:VETO | US$1.09B | US$848.9M | 17.4× | 1.5× | 7.0× | 1.6× | 10.9% | 0.0× | n/a |
| North China Pharmaceutical Company Ltd. Class A · SSE:600812 | US$1.09B | US$1.55B | 81.1× | 1.3× | n/a | 1.3× | 1.1% | 0.8× | n/a |
| Basilea Pharmaceutica AG · SIX:BSLN | US$1.07B | US$964.4M | 22.4× | 3.5× | 15.2× | 5.6× | 17.3% | 0.5× | n/a |
| Beijing Foyou Pharma Co., Ltd. Class A · SSE:601089 | US$1.03B | US$710.8M | 18.7× | 1.3× | n/a | 1.8× | 10.2% | 0.0× | n/a |
| Chengdu Easton Biopharmaceuticals Co., Ltd. Class A · SSE:688513 | US$997.1M | US$737.6M | 24.4× | 3.8× | n/a | 2.2× | 20.9% | 0.0× | n/a |
| Jiangsu Kanion Pharmaceutical Co. Ltd. Class A · SSE:600557 | US$983.2M | US$677.1M | 20.8× | 1.3× | n/a | 1.3× | 9.4% | 0.0× | n/a |
| Median of the others | US$1.09B | US$947.1M | 22.4× | 2.5× | 14.2× | 1.8× | 9.8% | 0.0× | 1.31 |
Forecasts
Analysts' consensus from EODHD, read Nov 9, 2026. Not 6ix's view and not investment advice.
- Price target
- 21.08 CNY · Analysts' mean
- EPS, year to Dec 2026
- 0.84 · 1 analyst
- Revenue, year to Dec 2026
- 3.69B · 5 analysts
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Oct 29, 2026 | −1.1% |
| Q2 2026 | Aug 27, 2026 | +2.7% |
| Q1 2026 | Apr 28, 2026 | +1.9% |
| Q3 2025 | Oct 25, 2025 | +2.2% |
| Q2 2025 | Aug 26, 2025 | −4.3% |
| Q1 2025 | Apr 2, 2025 · Before open | −0.8% |
| Q3 2024 | Oct 29, 2024 · Before open | −3.1% |
| Q2 2024 | Aug 24, 2024 | −4.6% |
| Q1 2024 | Apr 25, 2024 · After close | −2.5% |
| Q4 2023 | Mar 29, 2024 · Before open | +4.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q3 2023 | Oct 25, 2023 · Before open | −0.1% |
| Q2 2023 | Aug 25, 2023 · After close | +5.6% |
| Q1 2023 | Apr 26, 2023 · After close | −3.2% |
| Q4 2022 | Mar 31, 2023 · After close | −0.2% |
| Q3 2022 | Oct 25, 2022 · After close | +5.3% |
| Q2 2022 | Aug 25, 2022 · Before open | +4.0% |
| Q1 2022 | Apr 28, 2022 · Before open | −5.0% |
| Q4 2021 | Mar 25, 2022 · After close | −2.5% |
| Quarter to Sep 30, 2021 | Oct 26, 2021 · After close | −8.5% |
| Quarter to Jun 30, 2021 | Aug 26, 2021 · Before open | −3.2% |
Financials
Annual, in CNY
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.40B | 3.07B | 2.71B | 2.08B | 2.01B | 2.00B | 1.47B | 1.19B | 1.05B | 969.9M |
| Cost of revenue | 2.00B | 1.82B | 1.53B | 1.07B | 969.3M | 920.8M | 700.4M | 593.9M | 492.1M | 413.6M |
| Gross profit | 1.40B | 1.25B | 1.18B | 1.01B | 1.04B | 1.08B | 766.2M | 596.0M | 555.2M | 556.2M |
| Research and development | 253.0M | 206.6M | 172.9M | 132.7M | 117.7M | 111.5M | 94.8M | 80.3M | 85.3M | 76.6M |
| Selling, general and administrative | 351.1M | 188.9M | 174.0M | 142.8M | 150.3M | 165.1M | 141.4M | 110.1M | 103.0M | 174.4M |
| Operating income | 441.8M | 373.2M | 569.7M | 416.6M | 499.4M | 513.1M | 263.1M | 161.7M | 142.1M | 149.5M |
| Depreciation and amortization | 223.6M | 204.9M | 141.0M | 115.6M | 91.6M | 95.7M | 91.3M | 91.8M | 90.5M | 77.2M |
| EBITDA | 665.4M | 578.1M | 710.8M | 532.2M | 590.9M | 608.9M | 354.4M | 253.4M | 232.6M | 226.7M |
| Interest expense | 35.2M | 33.0M | 26.7M | 29.0M | 24.3M | 27.7M | 25.1M | 17.7M | 15.9M | 10.4M |
| Income before tax | 470.7M | 368.3M | 571.2M | 413.8M | 487.8M | 510.9M | 259.9M | 161.9M | 144.5M | 178.5M |
| Income tax | 38.5M | 56.2M | 40.0M | 54.2M | 71.4M | 36.1M | 20.9M | 19.7M | 25.2M | |
| Net income | 400.5M | 300.7M | 453.6M | 346.7M | 412.8M | 398.2M | 194.4M | 119.0M | 104.9M | 132.8M |
| Earnings per share, basic | 0.86 | 0.65 | 0.98 | 0.75 | 1.03 | 1.01 | 0.49 | 0.29 | 0.26 | 0.34 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 651.2M | 487.4M | 335.4M | 384.4M | 1.31B | 294.5M | 396.4M | 287.9M | 397.8M | 295.0M |
| Short-term investments | 1.04B | 1.45B | 1.28B | 1.50B | 577.9M | 399.8M | 385.3M | 277.2M | 207.8M | 263.6M |
| Receivables | 983.6M | 1.14B | 1.02B | 742.5M | 606.6M | 466.6M | 373.1M | 399.8M | 351.1M | 312.7M |
| Inventory | 502.1M | 499.6M | 389.9M | 367.1M | 360.5M | 364.0M | 263.6M | 258.3M | 236.8M | 218.9M |
| Current assets | 3.37B | 3.65B | 3.26B | 3.09B | 3.06B | 1.60B | 1.53B | 1.36B | 1.32B | 1.17B |
| Property, plant and equipment | 1.30B | 1.11B | 1.03B | 953.9M | 929.3M | 935.6M | ||||
| Goodwill | 443.0M | 442.3M | 67.8M | 67.8M | 67.8M | 67.8M | 67.8M | 67.8M | 67.8M | 70.1M |
| Total assets | 7.66B | 7.97B | 6.60B | 6.11B | 5.69B | 3.90B | 3.56B | 3.00B | 2.92B | 2.73B |
| Accounts payable | 436.8M | 550.2M | 562.0M | 148.5M | 65.4M | 22.2M | 201.6M | 203.6M | 175.6M | 173.1M |
| Current liabilities | 1.89B | 2.25B | 1.34B | 1.31B | 1.12B | 877.2M | 1.05B | 665.5M | 657.3M | 518.1M |
| Long-term debt | 368.4M | 513.8M | 307.1M | 191.2M | 90.1M | 98.1M | 55.3M | 9.23M | 15.4M | |
| Total debt | 1.32B | 872.1M | 877.7M | 739.0M | 560.6M | 638.1M | 353.6M | 388.2M | 254.9M | |
| Total liabilities | 2.47B | 2.96B | 1.79B | 1.61B | 1.37B | 1.16B | 1.21B | 744.0M | 748.0M | 627.7M |
| Shareholders' equity | 4.70B | 4.47B | 4.50B | 4.22B | 4.03B | 2.46B | 2.12B | 2.01B | 1.95B | 1.90B |
| Shares outstanding | 464.8M | 460.3M | 463.5M | 463.0M | 402.4M | 396.0M | 397.1M | 404.6M | 404.5M | 394.2M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 297.5M | 735.5M | 378.2M | 389.5M | 382.6M | 388.4M | 383.6M | 174.9M | 107.6M | 207.7M |
| Capital spending | -176.1M | -185.3M | -244.5M | -372.4M | -305.9M | -259.2M | -229.7M | -112.4M | -108.9M | -128.1M |
| Free cash flow | 121.4M | 550.2M | 133.7M | 17.1M | 76.8M | 129.3M | 153.9M | 62.4M | -1.30M | 79.5M |
| Cash from investing | -451.7M | -161.0M | -1.24B | -627.1M | -243.1M | -397.8M | -145.4M | -58.3M | -450.0M | |
| Cash from financing | -133.3M | -272.5M | -48.3M | 1.26B | -169.9M | 92.6M | -125.9M | 76.9M | 294.6M | |
| Dividends paid | -167.5M | -215.8M | -162.8M | -163.7M | -160.1M | -100.1M | -60.7M | -80.3M | -75.1M | -70.0M |
| Share buybacks | -115.1M | -44.9M | -1.79M | -915.9K | -100.5M | |||||
| Change in cash | 149.3M | 151.3M | -55.2M | -903.5M | 1.02B | -24.5M | 78.5M | -96.5M | 126.2M | 52.3M |
Cap table
Built by 6ix from Tianjin Ringpu Bio-technology Co., Ltd. Class A’s releases
- Common shares
- 464,754,706
- Fully diluted
- 464,754,706
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 464,754,706 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 464,754,706 |
Log in to ask 6ix AI your own questions about Tianjin Ringpu Bio-technology Co., Ltd.